About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in San Antonio | 12,572 Studies Near You | Clareo Health

Clinical Trials LocationsSan Antonio

Clinical Trials in San Antonio

Discover 12,572 clinical trials near San Antonio, Texas. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 2361-2380 of 12,572 trials

RECRUITINGNA< 1 mile

Post-Market Study to Assess iTind Safety in Comparison to UroLift

NCT04757116

The study objective is to evaluate the safety of the iTind device comparied to UroLift.

Benign Prostatic Hyperplasia (BPH)

Olympus Corporation of the Americas206 participantsStarted Sep 2022

Phoenix, Arizona, United States • Tucson, Arizona, United States • Fresno, California, United States +15 more locations

Active Not RecruitingPhase 2< 1 mile

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

NCT06116916

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Diabetic Macular Edema (DME)

Kyowa Kirin Co., Ltd.150 participantsStarted Jan 2024

Mesa, Arizona, United States • Tucson, Arizona, United States • Arcadia, California, United States +84 more locations

Find Trials by Condition in San Antonio

Breast Cancerin San Antonio Lung Cancerin San Antonio Prostate Cancerin San Antonio Colorectal Cancerin San Antonio Melanomain San Antonio Leukemiain San Antonio Lymphomain San Antonio Pancreatic Cancerin San Antonio Ovarian Cancerin San Antonio Brain Cancerin San Antonio

Data from ClinicalTrials.govTerms

Active Not Recruiting< 1 mile

OCS Heart Perfusion Post-Approval Registry

NCT05047068

The objective of this post-approval registry is to provide additional real-world evidence of the performance of the OCS Heart System to preserve DBD and DCD donor hearts.

TransMedics350 participantsStarted Sep 2021

Los Angeles, California, United States • Palo Alto, California, United States • San Francisco, California, United States +24 more locations

Active Not RecruitingPhase 2< 1 mile

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

NCT06116890

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Neovascular Age-Related Macular Degeneration (nAMD)

Kyowa Kirin Co., Ltd.180 participantsStarted Jan 2024

Mesa, Arizona, United States • Tucson, Arizona, United States • Arcadia, California, United States +81 more locations

COMPLETEDPhase 1/2< 1 mile

Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

NCT06863467

Gemini is being evaluated in a placebo controlled, single dose, escalating dose study to evaluate the safety and tolerability of intravenous Gemini in adult subjects with stage 3 or 4 chronic kidney disease. Pharmacokinetics will be evaluated and measurements of the effect of Gemini on pharmacodynamic activity will be measured to assess changes in potential pharmacodynamic markers.

Renal Insufficiency, ChronicChronic Kidney Disease stage3Chronic Kidney Disease stage4

Revelation Biosciences, Inc40 participantsStarted Jan 2025

Chula Vista, California, United States • La Mesa, California, United States • San Antonio, Texas, United States

RECRUITINGPhase 2< 1 mile

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

NCT06824987

The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.

APOL1-Mediated Kidney Disease

AstraZeneca96 participantsStarted Mar 2025

Alabaster, Alabama, United States • Birmingham, Alabama, United States • Irondale, Alabama, United States +74 more locations

Active Not RecruitingPhase 1< 1 mile

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called treatment arms. The Recommended Phase 2 dose (RP2D) will be explored. Each treatment arm receives a different dose of ABBV-400. This study will include a dose escalation phase to determine the best dose of ABBV-400, followed by a dose expansion phase to confirm the dose and combination with bevacizumab. Approximately 500 adult participants with NSCLC, gastroesophageal adenocarcinoma/gastroesophagel junction adenocarcinoma (GEA) and colorectal cancer (CRC) or advanced solid tumors, will be enrolled in the study in approximately 7-10 sites in the Dose Escalation phase and 85-95 sites in the Dose Expansion phase worldwide. Dose escalation arms, participants will receive intravenous (IV) escalating doses of ABBV-400 monotherapy. Dose expansion arms, participants in the following advanced solid tumor indications: non-squamous NSCLC with wildtype EGFR-expression (wtEGFR NSCLC) \[Part 2i\] or mutated EGFR-expression (mutEGFR NSCLC) \[Part 2ii\], squamous NSCLC \[Part 2iii\], GEA \[Part 3\] will receive intravenous (IV) ABBV-400 monotherapy, participants CRC will receive IV ABBV-400 monotherapy in expansion \[Part 4\], participants MET amplification will receive IV ABBV-400 monotherapy in expansion \[Part 5\], participants MET mutation will receive IV ABBV-400 monotherapy in expansion \[Part 6\], participants CRC safety lead in will receive escalating doses of IV ABBV-400 in combination with IV bevacizumab \[Part 7a\], and participants CRC dose optimization in will the low or high dose of IV ABBV-400 determined in Part 7a in combination with IV bevacizumab or oral trifluridine/tipiracil (TAS-102) tablets \[Part 7b\]. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Non-Small Cell Lung CancerAdvanced Solid TumorsGastroesophageal Adenocarcinoma+1 more

AbbVie520 participantsStarted Oct 2021

Los Angeles, California, United States • Aurora, Colorado, United States • New Haven, Connecticut, United States +79 more locations

COMPLETEDPhase 274 miles

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

NCT04892706

The safety and efficacy of once daily application of IDP 126 Gel will be compared to Epiduo® Forte and IDP-126 Vehicle Gel.

Bausch Health Americas, Inc.686 participantsStarted Jun 2021

Bryant, Arkansas, United States • Rogers, Arkansas, United States • Fremont, California, United States +39 more locations

COMPLETEDPhase 2154 miles

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

NCT03694002

This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known if giving carboplatin and paclitaxel with or without ramucirumab will work better in treating patients with thymic cancer.

Locally Advanced Thymic CarcinomaMetastatic Thymic CarcinomaRecurrent Thymic Carcinoma+1 more

SWOG Cancer Research Network21 participantsStarted Mar 2019

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +251 more locations

Active Not RecruitingPhase 4187 miles

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

NCT03229200

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.

Lymphoma, B-CellLymphoma, Non-HodgkinLeukemia, B-cell+2 more

Pharmacyclics Switzerland GmbH297 participantsStarted May 2017

Burbank, California, United States • Duarte, California, United States • La Jolla, California, United States +95 more locations

Active Not RecruitingNA190 miles

Study of Posterior Cervical Stabilization System (PCSS) as Part of Circumferential Fusion to Treat Multilevel DDD

NCT04229017

This study will evaluate the safety and effectiveness of a device called "Posterior Cervical Stabilization System or PCSS" when used along with posterior cervical fusion (PCF) in combination with anterior cervical discectomy and fusion (ACDF) in the treatment of multi-level cervical degenerative disease.

Degenerative Disc Disease

Providence Medical Technology, Inc.236 participantsStarted Mar 2020

Phoenix, Arizona, United States • Encinitas, California, United States • Los Gatos, California, United States +14 more locations

RECRUITINGPhase 4190 miles

Individualizing Treatment for Asthma in Primary Care (Full Study)

NCT07052942

While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long term side effects. This study will compare two currently available approaches to reduce AEX in primary care patients: (1) use of inhaled corticosteroids (ICS) as part of rescue therapy, also known as MART (Maintenance And Reliever Therapy) or PARTICS (Patient Activated Reliever Trigger Inhaled Corticosteriods) therapy - either of these therapies will be called Rescue-Inhaled Corticosteroids or R-ICS pronounced "Ricks," and (2) use of azithromycin (AZ) as a preventive therapy. These treatments will be studied both individually and in combination.

AsthmaAsthma AttackAsthma Exacerbations

DARTNet Institute3,200 participantsStarted Aug 2025

Aurora, Colorado, United States • Aurora, Colorado, United States • Orlando, Florida, United States +10 more locations

RECRUITING190 miles

STXBP1 and SYNGAP1 Related Disorders Natural History Study

NCT06555965

The purpose of this study is to find out more about STXBP1 and SYNGAP1 related disorders. The information gathered by this study will be used to prepare for clinical treatment trials. The primary objective of the study is to better define and outline the clinical spectrum of STXBP1 and SYNGAP1 through detailed developmental, seizure, and quality of life assessments as an extension of routine clinical care.

Genetic DiseaseSTXBP1 Encephalopathy With EpilepsySYNGAP1-Related Intellectual Disability

Children's Hospital of Philadelphia600 participantsStarted Aug 2023

Palo Alto, California, United States • Aurora, Colorado, United States • New York, New York, United States +2 more locations

Active Not RecruitingPhase 2190 miles

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

NCT03069378

The purpose of this study is to determine how well the combination of therapy of talimogene laherparepvec (T-VEC) and pembrolizumab works in the treatment of patients with sarcoma.

SarcomaEpithelioid SarcomaCutaneous Angiosarcoma

Memorial Sloan Kettering Cancer Center41 participantsStarted Mar 2017

Menlo Park, California, United States • Stanford, California, United States • Harrison, New York, United States +2 more locations

TERMINATEDPhase 1/2190 miles

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

NCT05081388

Primary Objectives Phase 1 (Safety and Tolerability) • Evaluate the safety and tolerability of REGN14256+imdevimab and REGN14256 monotherapy, as measured by treatment-emergent adverse events (TEAEs), injection-site reactions (ISRs), and hypersensitivity reactions Phase 1/2 (Virologic Efficacy) • Evaluate the virologic efficacy of REGN14256+imdevimab and REGN14256 monotherapy compared to placebo, as measured by time-weighted average (TWA) change from baseline in viral load through day 7 Phase 1/2/3 (Clinical Efficacy) • Evaluate the clinical efficacy of REGN14256+imdevimab compared to placebo, as measured by COVID-19 symptoms resolution Secondary Objectives Phase 1 (Safety and Tolerability) • Evaluate the safety and tolerability of REGN14256+imdevimab and REGN14256 monotherapy, as measured by treatment-emergent serious adverse events (SAEs) Phase 2 and Phase 3 (Safety and Tolerability) • Evaluate the safety and tolerability of REGN14256+imdevimab and REGN14256 monotherapy, as measured by TEAEs, ISRs, hypersensitivity reactions, and SAEs Phase 1, Phase 2, and Phase 3 (Virologic Efficacy, Drug Concentration, and Immunogenicity) * Evaluate additional indicators of virologic efficacy of REGN14256+imdevimab and REGN14256 monotherapy * Characterize the concentration-time profile of REGN14256 administered in combination with imdevimab or alone as a monotherapy * Assess the immunogenicity of REGN14256 administered in combination with imdevimab or alone as a monotherapy

Regeneron Pharmaceuticals25 participantsStarted Nov 2021

La Mesa, California, United States • Long Beach, California, United States • Mission Viejo, California, United States +25 more locations

RECRUITING217 miles

FebriDx® Pediatric Validation Study

NCT07211997

The primary objective of this study is to determine performance characteristics of the FebriDx® test in differentiating bacterial from non-bacterial etiology among febrile pediatric patients (2-11 years) presenting to the emergency department, urgent care center or primary care office with a suspected acute respiratory tract infection.

Acute Respiratory Infections (ARIs)

Lumos Diagnostics800 participantsStarted Oct 2025

Colton, California, United States • Clearwater, Florida, United States • Lutz, Florida, United States +7 more locations

COMPLETEDPhase 2507 miles

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

NCT04875195

The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab every six weeks (Q6W).

Hodgkin's LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)

Merck Sharp & Dohme LLC66 participantsStarted Jun 2021

Torrance, California, United States • New Orleans, Louisiana, United States • Annapolis, Maryland, United States +24 more locations

COMPLETEDPhase 2793 miles

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

NCT04220866

The purpose of this study is to assess the efficacy and safety of intratumoral (IT) ulevostinag PLUS pembrolizumab (MK-3475) compared to pembrolizumab alone as a first line treatment of adults with metastatic or unresectable, recurrent head and neck squamous cell carcinoma (HNSCC). The primary study hypotheses are that IT ulevostinag in combination with pembrolizumab results in a superior Objective Response Rate (ORR), per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), compared to pembrolizumab alone: 1. In participants with a tumor that has a programmed cell death-ligand 1 (PD-L1) Combined Positive Scoring (CPS) ≥ 1, and 2. In participants with a tumor that has a PD-L1 CPS ≥ 20.

Head and Neck Squamous Cell Carcinoma (HNSCC)

Merck Sharp & Dohme LLC18 participantsStarted Mar 2020

Los Angeles, California, United States • San Francisco, California, United States • Detroit, Michigan, United States +31 more locations

COMPLETEDPhase 3931 miles

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)

NCT05096403

The purpose of the study is to determine the efficacy of pegcetacoplan administration compared to placebo in increasing hemoglobin (Hgb) level from baseline and avoiding transfusion in participants with primary cold agglutinin disease (CAD).

Cold Agglutinin Disease

Swedish Orphan Biovitrum24 participantsStarted Oct 2022

Whittier, California, United States • Miami Lakes, Florida, United States • Iowa City, Iowa, United States +41 more locations

COMPLETEDNA1028 miles

Clinical Validation Study of the Eximis CS (Contained Segmentation) System

NCT06572163

The purpose of this study is to evaluate device safety and effectiveness of the Eximis CS System.

Laparoscopic Gynecological Surgical Procedures

Eximis Surgical23 participantsStarted Sep 2024

Celebration, Florida, United States • Idaho Falls, Idaho, United States • Brooklyn, New York, United States +1 more locations

PreviousPage 119 of 629Next

Diabetes

in San Antonio

Heart Diseasein San Antonio